Department of Orthopaedic Surgery, The Affiliated Southeast Hospital of Xiamen University, Orthopaedic Center of People's Liberation Army, Zhangzhou, Fujian Province, China.
Department of Pathology, The Affiliated Southeast Hospital of Xiamen University, Orthopaedic Center of People's Liberation Army, Zhangzhou, Fujian Province, China.
Medicine (Baltimore). 2021 Jul 9;100(27):e26535. doi: 10.1097/MD.0000000000026535.
Accumulating studies have focused on the clinicopathological and prognostic roles of large intergenic noncoding RNA regulator of reprogramming (lincRNA-ROR) in cancer patients. However, the results were controversial and unconvincing. Thus, we performed a meta-analysis to assess the associations between lincRNA-ROR expression and survival and clinicopathological characteristics of cancer patients.
Hazard ratios for overall survival and disease-free survival with their 95% confidence intervals were used to evaluate the role of lincRNA-ROR expression in the prognosis of cancer patients. Risk ratios with their 95% confidence intervals were applied to assess the relationship between lincRNA-ROR expression and clinicopathological parameters.
A total of 18 articles with 1441 patients were enrolled. Our results indicated that high lincRNA-ROR expression was significant associated with tumor size, TNM stage, clinical stage, lymph metastasis, metastasis and vessel invasion of cancer patients. There were no correlations between high lincRNA-ROR expression and age, gender, infiltration depth, differentiation, serum CA19-9 and serum CEA of cancer patients. In addition, high lincRNA-ROR expression was associated with shorter Overall survival and disease-free survival on both univariate and multivariate analyses. Meanwhile, there were no obvious publication bias in our meta-analysis.
LincRNA-ROR expression was associated with the clinicopathological features and outcome of cancer patients, which suggested that lincRNA-ROR might serve as a potential biomarker for cancer prognosis.
Since this study is on the basis of published articles, ethical approval and informed consent of patients are not required.
越来越多的研究集中在长链非编码 RNA 调控重编程（lincRNA-ROR）在癌症患者中的临床病理和预后作用。然而，结果存在争议，缺乏说服力。因此，我们进行了一项荟萃分析，以评估 lincRNA-ROR 表达与癌症患者生存和临床病理特征之间的相关性。
使用总体生存率和无病生存率的风险比及其 95%置信区间来评估 lincRNA-ROR 表达在癌症患者预后中的作用。使用风险比及其 95%置信区间来评估 lincRNA-ROR 表达与临床病理参数之间的关系。
共纳入 18 篇文章，包含 1441 名患者。我们的结果表明，高 lincRNA-ROR 表达与肿瘤大小、TNM 分期、临床分期、淋巴转移、转移和血管浸润显著相关。高 lincRNA-ROR 表达与癌症患者的年龄、性别、浸润深度、分化、血清 CA19-9 和血清 CEA 之间没有相关性。此外，高 lincRNA-ROR 表达与单因素和多因素分析中的总生存率和无病生存率缩短相关。同时，我们的荟萃分析没有明显的发表偏倚。
lincRNA-ROR 表达与癌症患者的临床病理特征和预后相关，这表明 lincRNA-ROR 可能作为癌症预后的潜在生物标志物。
由于本研究基于已发表的文章，因此不需要患者的伦理批准和知情同意。
